

Series C | May 2021



**Brendan Frey, Founder and CEO | Amanda Kay, CBO | Ferdinand Massari, CMO
Matt Cahill, Head of Finance & Business Operations**



**The digital nature of RNA therapies
has sparked a revolution**

CCCAAATGCACTCCTGG

**Winning will require mastering the
enormous complexity of RNA biology**

**Digital RNA
Biology Platform**

X

**10¹⁷ Bytes
Data**


X

**Artificial
Intelligence**

=  **deep
genomics**

**Programming the best RNA therapies
for almost any gene in any genetic condition**

A digital framework for untangling complexity



DIGITAL GENETIC TARGET

DIGITAL RNA THERAPY

DIGITAL RNA BIOLOGY

Our platform is now ready for expansion




AI Platform & Preclinical
Research



Clinical & Business
Development

Team in place to execute our mission



Amanda Kay PhD
Chief Business Officer



Brendan Frey PhD FRSC
Founder & CEO




Matt Cahill MBA JD PhD
Head of Finance, Bus. Ops



Ferd Massari MD
Chief Medical Officer



Jeffrey Brown PhD
Head of Preclinical Res.



Strategic & Scientific Advisors



Steve Jurvetson
Strategic Advisor



Peter Barton Hutt
Strategic Advisor



Steven Dowdy
Scientific Advisor
UC San Diego
School of Medicine



Jennifer Cook
Special Advisor to CEO



Yann LeCun, PhD
Scientific Advisor



Vinod Khosla
Strategic Advisor
khosla ventures



Board Members



Adam D'Augelli
true Ventures



Alex Morgan
khosla ventures



Tom Hughes
NAVITOR



Maryanna Saenko
FUTURE VENTURES


Brendan Frey & Matt Cahill



Our digital AI Workbench predicts drug discovery outcomes up front



TRADITIONAL APPROACH - SEQUENTIALLY DERISK - EXPERIMENTAL TRIAL & ERROR - BESPOKE



DEEP GENOMICS' ADVANTAGE:

PREDICTION AT SCALE - DERISK ALL UP FRONT - ITERATIVE LEARNING


Predictors drive portfolio productivity, and we have 40 of them

EXAMPLE APPLICATIONS


- Identify novel targets
- Design therapies
- Predict safety and toxicity
- Identify new patient populations
- Predict drug properties

SBO PREDICTORS


- Protein restoration
- Protein expression Increase
- Protein knockdown



Data driven prediction, positive feedback loops, and exponential growth



Tackling complexity - Our digital AI Workbench unlocks targets across the spectrum of genetic types



AI Workbench and “plug-and-play” SBO technology powers high-value, low risk therapies



THERAPEUTIC AREA

CNS

Frontotemporal Dementia

Niemann-Pick Disease Type C

Pediatric Epilepsy

Parkinson’s Disease

Metabolic

Wilson Disease

Refractory Gout

Partnered

Undisclosed


Undisclosed

Undisclosed

Undisclosed

Target Identification

Under Assessment



Our digital AI Workbench is designed to drive outsized returns



Our AI Workbench...

Can be applied broadly:
Mendelian to complex disease

Can unwind complex RNA biology:
Program genetic RNA therapy to genetic cause

Learns:
Iteration enhances prediction; prediction enables scale and speed




Deliver **Programs Near-term** and
Unlock **Novel Targets** in
Larger Indications

High Probability Of Success
Preclinical: 10% → 50%
Clinical: Targets Cause

Cohorts of Medicines

DG Portfolio: At tipping point to significant clinical expansion



Series C: Investing \$180M to expand our digital AI platform and advance cohorts of programs




PREDICTORS

Expand AI for complex disease, SBO effect and SBO safety



GENES SCREENED

60 complex, 40 Mendelian
Enabled by AI and robotics



TARGETS WITH PATENTED LEADS

Complex and Mendelian



EXPAND PARTNERSHIPS

Broaden pipeline, access non-dilutive funding



PRECLINICAL PROGRAMS

Internal, partners, CRO



PROGRAMS IN THE CLINIC

Est \$4.5B peak sales